Clinical Trial Update: A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg [Phase 2]

View source ↗

Summary

A Phase 2 study comparing threeFulvestrant dosing regimens (250 mg, 250 mg with loading, and 500 mg) in advanced breast cancer and metastatic breast cancer to e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-08-29